Visualmed (@visualmedapp) 's Twitter Profile
Visualmed

@visualmedapp

Visualmed app provides #VisualAbstract of landmark clinical trials on the go for quick reference! Available on android and iPhone. Created by @usamanasirmd

ID: 972326317176827904

linkhttps://apps.apple.com/us/app/visualmed/id1423485924 calendar_today10-03-2018 04:20:33

625 Tweet

3,3K Followers

4,4K Following

Visualmed (@visualmedapp) 's Twitter Profile Photo

🚨 New #ClinicalTrial ALERT! 🚨 TRACE-III: Tenecteplase improves outcomes in ischemic stroke without thrombectomy. 33% vs. 24% maintained mRS 0-1 at 90 days! πŸ™Œ Less disability, similar survival, but watch out for higher bleeding risk. 🩸 #Stroke #MedTwitter Visualmed

🚨 New #ClinicalTrial ALERT! 🚨 TRACE-III: Tenecteplase improves outcomes in ischemic stroke without thrombectomy. 33% vs. 24% maintained mRS 0-1 at 90 days! πŸ™Œ Less disability, similar survival, but watch out for higher bleeding risk. 🩸 #Stroke #MedTwitter <a href="/Visualmedapp/">Visualmed</a>
Visualmed (@visualmedapp) 's Twitter Profile Photo

πŸ“Š New findings from the 2024 REVISE Trial! Pantoprazole reduces upper GI bleeding in ICU patients on mechanical ventilation, with no effect on mortality. πŸ₯ 1.0% (pantoprazole) vs. 3.5% (placebo) for GI bleeding. Stay updated with Visualmed ! #CriticalCare #MedTwitter

πŸ“Š New findings from the 2024 REVISE Trial! Pantoprazole reduces upper GI bleeding in ICU patients on mechanical ventilation, with no effect on mortality. πŸ₯

1.0% (pantoprazole) vs. 3.5% (placebo) for GI bleeding.

Stay updated with <a href="/Visualmedapp/">Visualmed</a> ! #CriticalCare #MedTwitter
Royce Copeland (@royce_copeland1) 's Twitter Profile Photo

Ryan D'Souza, MD Other great medicine apps: -Read and Browzine for organizing my favorite research articles and journals -VisualMed for summarizing articles

Usama Nasir MD (@usamanasirmd) 's Twitter Profile Photo

Excited to announce the launch of the first-ever interactive 3D heart simulator for patient education! If you work in the field of cardiology, we'd love to have you on board as a beta tester for our app. Please DM if you're interested in trying it out! #CardioTwitter #Cardiology

Excited to announce the launch of the first-ever interactive 3D heart simulator for patient education! If you work in the field of cardiology, we'd love to have you on board as a beta tester for our app. Please DM if you're interested in trying it out! #CardioTwitter #Cardiology
Usama Nasir MD (@usamanasirmd) 's Twitter Profile Photo

It's always difficult to explain #AFib to patients and how it can ⬆️ risk of stroke. With #HeartVision app, we have made it slightly easier to explain why anticoagulation is important in AFib by visualizing it in fully interactive format! #CardioTwitter #MedTwitter check it out

Usama Nasir MD (@usamanasirmd) 's Twitter Profile Photo

Happy to announce! πŸŽ‰ Visualmed now contains 1,500 landmark clinical trials summarized as visual abstracts. We add 3-4 new trials weekly. An invaluable tool for staying up-to-date with the latest in medical literature. πŸ“š #MedEd #ClinicalTrials #MedicalResearch #MedTwitter

Visualmed (@visualmedapp) 's Twitter Profile Photo

The ESPRIT Trial found that lowering SBP to <120 mm Hg in high-risk patients reduces major cardiovascular events (HR 0.88) but slightly increases the risk of syncope (HR 3.00).#Cardiology #Hypertension #MedTwitter #CardioTwitter

The ESPRIT Trial found that lowering SBP to &lt;120 mm Hg in high-risk patients reduces major cardiovascular events (HR 0.88) but slightly increases the risk of syncope (HR 3.00).#Cardiology #Hypertension #MedTwitter #CardioTwitter
Visualmed (@visualmedapp) 's Twitter Profile Photo

The ABYSS trial found that interrupting long-term beta-blocker treatment after MI was not noninferior to continuing therapy for preventing cardiovascular events. Continuation of beta-blockers remains the safer approach. #Cardiology #CardioTwitter #MI #ESC2024 #MedTwitter

The ABYSS trial found that interrupting long-term beta-blocker treatment after MI was not noninferior to continuing therapy for preventing cardiovascular events. Continuation of beta-blockers remains the safer approach. #Cardiology #CardioTwitter #MI #ESC2024 #MedTwitter